In addition to the proteins controlling cancer cell proliferation and apoptosis, our proteomics results found that PEPE2 administration could interfere with DPYSL3 expression in cancer cells, which is involved in cell adhesion and the metastasis of various tumors, such as breast cancer [34], lung cancer [35], gastric cancer [36], and prostate cancer [37]. Here, DPYSL3 is linked to prostate cancer.